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Abstract
Communication among cells via direct cell-cell contact by connexin gap junctions, or between cell and extracellular
environment via pannexin channels or connexin hemichannels, is a key factor in cell function and tissue homeostasis.
Upon malignant transformation in different cancer types, the dysregulation of these connexin and pannexin channels
and their effect in cellular communication, can either enhance or suppress tumorigenesis and metastasis. In this review,
we will highlight the latest reports on the role of the well characterized connexin family and its ability to form gap
junctions and hemichannels in cancer. We will also introduce the more recently discovered family of pannexin
channels and our current knowledge about their involvement in cancer progression.
Background
Intercellular communication between cells is realized
through gap junction channels formed by connexins
(Cx). In the last decade or so, connexin hemichannels
were identified, which mediate the communication be-
tween intracellular and the extracellular microenviron-
ment [1, 2]. It is well documented that gap junctional
intercellular communication is important in mediating
normal cell growth, differentiation, and development. The
roles of non-coupling hemichannels started to emerge [3],
mostly resulting in the disruption of normal homeostasis,
although under mechanical stimulation they mediate the
release of important anabolic factors in bone cells [4, 5].
Among the various types of connexins, mutations of
connexins or loss of functional channels are implicated in
many diseases and disorders, including congenital deaf-
ness, skin disorders, cataracts and cancers [6, 7].
Pannexin channels on the other hand (Panx1, 2 and 3), are
a recently discovered family [8] of single membrane channel-
forming glycoproteins expressed in many organs of the hu-
man body [9–11]. Pannexins were first discovered due to
their limited sequence homology to innexins [9] (invertebrate
gap junctions), and were initially proposed as a new family of
mammalian gap junction proteins, complementary to
connexins [12]. Although their capacity to form gap junc-
tions remains controversial [13, 14], we and others have
shown that their main function is to form large-pore sin-
gle membrane channels for the release of ATP and other
metabolites important for cellular communication and
autocrine/paracrine signaling [10, 15–19]. Panx1 has
been reported to be ubiquitously expressed in most mam-
malian cells and tissues [9, 10]. Panx2 is expressed in neu-
rons of the central nervous system and many other tissues
as was recently reported [20]. Panx2 has been linked to
modulation of neuronal commitment, being differentially
expressed in postnatal neural progenitor cells and mature
neurons [21]. Panx3 is expressed mostly in keratinocytes,
chondrocytes and osteoblasts where it regulates cell prolif-
eration and differentiation [9, 18, 19, 22, 23].
Panx1 represents the best characterized member of
the family. Panx1 is N-glycosylated at residue N254 in
the second extracellular loop (EL2) [10, 24], and this
modification regulates its localization in the cell and the
ability of Panx1 to intermix with other pannexins [16].
Six subunits of Panx1 can oligomerize into a hexamer
[24] to form a channel that is thought to be gated closed
by its carboxyl terminal tail (CT), interacting with the
intracellular loop (IL) in a ball-and-chain fashion [25, 26].
The regulation of Panx1 channel opening is not well
understood, but individual cysteine and tyrosine residues
in the intracellular loop of the protein appear to be critical
for Panx1 channel function [27–30]. The large-pore Panx1
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channel can allow passage of molecules of ~1 kDa when
open (500 pS), and it can be activated by voltage, high
extracellular K+, high intracellular Ca2+ and mechano-
sensitive stimuli among others [17, 31]. Panx1 has been
proposed to have a role in inflammation [32–34].
Additionally, Panx1 channels can be irreversibly opened
by caspase cleavage of the CT, activating the release of
ATP as a ‘find-me’ signal for monocyte recruitment and
clearance of apoptotic lymphocytes [15].
In the current review, we will highlight the most
recent literature on the role of connexins in cancer, and
introduce the more recently discovered pannexin channels
and their proposed function in different cancer types.
Connexins and cancer
Cancer was one of the first pathologies found to be
associated with gap junction channel impairment, and
connexins have long been shown to possess tumor sup-
pressive function [35]. Cx43 as well as other members of
the connexin family such as Cx26 and Cx32 have been
demonstrated to inhibit primary tumor cell progression
when expressed in tumor cells [36–38]. However, con-
nexin expression has been positively correlated with
more invasive cancers and metastases [39, 40]. These
data suggest a more complex, cancer stage-specific func-
tion of connexins in cancer progression and metastasis.
Connexin expression is also reported to suppress cancer
behavior and this function is independent of their roles
in forming gap junction and hemichannels [41]. Many
review papers in recent years cover the topics related to
connexin and connexin-forming channels in cell cycle
progression and checkpoint control, cancer cell pro-
liferation and differentiation, cancer microenvironment,
tissue invasion and metastasis, and various cancer
pathologies and therapeutic potentials (for reviews, see
[7, 39, 40, 42–52]). In this review, we primarily focus on
studies published in the last couple of years (Table 1),
particularly concentrating on the underlying mecha-
nisms related to various states of cancer development
and their potential applications in cancer therapeutics.
Connexin channels in cell cycle progression, cell
proliferation and primary cancer growth
Loewenstein and Kanno first postulated that liver cancer
cells were different from normal liver cells in that they
lacked intercellular communication [53]. Since then,
there has been numerous studies dedicated to uncover
the role of gap junctions and connexins in tumor pro-
gression (reviewed by [6, 54, 55]). Reduced expression of
connexins and gap junctional communication has been
shown in many tumor types. Clinical studies also report
that deficient or abnormal connexins are frequently
found in tumor tissues and cell lines, such as breast can-
cer, prostate cancer, lung cancer, and many other cancer
types [7]. For example, Cx43 was found to be reduced in
breast carcinoma cells obtained from the primary
tumors of breast cancer patients [56]. In some cases,
decreased expression of connexins even occurs in pre-
cancerous lesions; Cx43 was found to be highly reduced
in cervical dysplasia, an early stage in malignant trans-
formation [57].
Many studies demonstrate that cancer cells lose their
capability of communication through gap junctions,
leading to the overall assumption that cancer cells do
not communicate. However, the situation is more com-
plicated than originally thought. Some cells completely
lack cell coupling, whereas others exhibit a slight
decrease compared to their normal counterparts [35].
While it is true that the tumorigenic behavior of cells is
not always correlated with a complete lack of cell-cell
communication, the forced inhibition of connexins and
cell coupling, such as knocking down connexin expres-
sion, has enhanced the tumorigenicity of carcinoma
cells. In vivo studies demonstrate the tumor suppressive
roles of Cx43 and Cx32, in which mice with decreased ex-
pression of Cx43 or Cx32 exhibit increased carcinogen-
induced tumor growth in comparison to control wild-type
mice, represented by an increase in number and size of
tumor nodules in the lung [58, 59]. A recent study showed
that ectopic expression of Cx43, not Cx26, suppresses cell
proliferation and anchorage-independent growth, and also
reduces size of melanomas when grown in the chicken
chorioallantoic membrane, a unique ex vivo system to
study cancer growth [60]. Additionally, inhibition of Cx43
gap junctions accelerates proliferation of four different
melanoma cell lines whereas as expected, increased coup-
ling through overexpression of Cx43 reduces cell growth
and melanoma tumor growth in vivo [61]. Increased inci-
dence of lung adenocarcinomas induced by 7,12-dimethyl-
benzanthracene (DMBA), a carcinogen, was observed in
Cx43 heterozygous knockout mice compared to wild-type
control mice [62]. Active vitamin D3, a chemo-preventive
agent, increases expression and assembly of Cx32 and pre-
vents androgen-induced degradation of Cx32 in human
prostate cancer cells [63]. Additionally, Cx32 gap junc-
tions sensitize cells to the growth inhibitory effect of
vitamin D3. Human cytomegalovirus (HCMV) is highly
prevalent in glioblastoma multiforme (GBM) and in other
tumors, and HCMV downregulates Cx43 protein and dis-
rupts gap junctional coupling, which is thought to be a
mechanism contributing to gliomagenesis [64]. Suppres-
sion of tumor growth also depends upon cancer cell types
and context. For example, Cx26 and Cx43 overexpression
in the breast cancer cell line, MDA-MB-231, inhibited
tumor growth in a three-dimensional (3D) environment
[40]. Cx43 exerts different degrees of inhibitory effects on
two breast adenocarcinoma cells, ER+ MCF-7 and triple
negative MDA-MB-231 cells. Interestingly, the effect on
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2D and 3D cultures of identical cancer cell type is also dif-
ferent [65].
The major effect of connexins and gap junctions on
suppression of primary cancer growth is a result of in-
hibition of cell cycle progression; however, until now
limited knowledge is gained regarding direct molecular
mechanisms governing the cell cycle cell events in can-
cer cells. An earlier evidence of the effect of Cx43 on cell
cycle is exemplified in C6 glioma cells, where the restor-
ation of Cx43 inhibits their progression to the S phase of
the cell cycle, owing in part to a reduction of cyclin E
expression and thus, the rate of proliferation [66]. Inter-
estingly, the restoration of Cx43 expression in glioma
cells diminishes c-Src activity. Additionally, a Cx43 mu-
tant lacking its c-Src phosphorylation sites is not able to
inhibit the c-Src activity and does not exhibit decreased
glioma proliferation. This suggests that c-Src phosphor-
ylation on the C-terminal tail of Cx43 is involved in the
anti-proliferative effects. This data suggests that Cx43
and c-Src are mutually regulated by a reciprocal
activation/inactivation loop via protein phosphorylation.
Gellhaus et al. [67] reported a direct link between Cx43
and the growth regulator protein CCN3, which is
involved in the anti-proliferative activity of neuroblast-
oma, glioma, and chronic myeloid leukemia. FRET ana-
lysis and co-immunoprecipitation results establish an
Table 1 Summary of the most recent progress in our understanding of connexin subtypes in growth and metastasis of various cancers
Connexin Cancer type Description Reference
Cx43 Breast Different effects on MCF-7 and MDA-MB231 in 2-D and 3-D cell cultures [65]
Cx43 Breast Peptide ACT1 increase GJ and impairs cell proliferation/survival [116]
Cx43 Breast CM from breast cancer cells decreases Cx43 gap junctions [96]
Cx43 Gastric cancer cells Increase in diapedesis and transmigration through intercellular space
between mesothelial cells
[90]
Cx43 Mammalian cancer stem-like cells miRNA-206 represses pro-apoptotic PDCD4 and Cx43 [76]
Cx43 Prostate With Snail-1 to repress E-cadherin and promotes EMT, mobility and
invasiveness
[88]
Cx43 Prostate Cx43 knockdown, not gap junctions inhibits migration/invasion of four
prostate cancer cell lines
[98]
Cx43 Osteosarcoma miRNA-23a suppresses Cx43 [77]
Cx43 Neuroblastoma & glioma, leukemia A direct link of Cx43 and CCN in anti-proliferative function [67]
Cx43 C6 glioma Cx43 antibody in rats increases survival and even more with radiotherapy [122]
Cx43 Glioma Cx43 increases resistance to TMZ via mitochondrial apoptosis pathway [136]
Cx43 Astrocytomas & glioblastomas Increased Cx43 expression in human tumors [125]
Cx43 Brain metastasis GJ with endothelial cells to promote metastatic lesion [86]
Cx43 Lung adenocarcinoma Increased incidence by DMBA in Cx43 heterozygous knockout mice [62]
Cx43 Non-small Lung cancer Cx43 reduction as a marker for cisplatin-chemotherapy [132]
Cx43 Non-small Lung cancer Cx43 overexpression reverses EMT and cisplatin resistance and deletion
has opposing effects
[134]
Cx43 Glioblastoma multiforme (GBM) HCMV reduces Cx43 and gap junctions [64]
Cx43 GBM Cx43 increased in TMZ-resistant cells by EGFR signaling [135]
Cx43 Mesothelioma Increases sensitivity to sunitinib via interaction with Bax [109]
Cx43 Oral carcinoma Cx43 correlates as a prognostic biomarker [130]
Cx43 HBV hepatocellular carcinoma Cx43 expression correlates with early tumor recurrence and survival [133]
Cx43 Ras-transformed NIH-3 T3 cell Cx43 5′ UTP active in transformed cell and 3′ UTP active in normal cell [72]
Cx32 Prostate Increased by Vit.D3 and sensitizes cells to growth inhibition by Vit.D3 [63]
Cx32 Pancreatic and prostate cancer Cx32 C-terminus required for growth and stability of gap junctions [68]
Cx37 Gastric tumors Cx37 siRNA negatively correlated with cancer development and promotes
apoptosis
[124]
Cx26 Cervical cancer-HeLa Redistribute cAMP and blocks cell cycle progression [69]
Cx46 & Cx43 Glioblastoma cancer stem cell Cx46, not Cx43 is detected; During differentiation, Cx46 reduced and Cx43
increased
[126]
Cx30 & Cx43 Breast Cx30 deletion and mutation in human tumors; Cx30/Cx43 as potential
prognostic markers
[128]
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interaction between CCN3 and the C-terminus of Cx43
in human embryonic kidney epithelial (293 T) cells. Sev-
eral variants of Cx43 with amino acid deletions were
generated, and the interaction of the Cx43 variants with
CCN3 was analyzed using FRET analysis. A 3D model of
the CCN3/Cx43 interaction complex was constructed,
and CCN3 specifically binds to the C-terminus of Cx43.
The ability of Cx43 to reduce the growth of 293 T cells
was facilitated by its binding with CCN3, leading to an
increase in endogenous CCN3. C-terminus of Cx32 is
shown to be not required for initiation of the assembly
of gap junctions, but for the further growth and stability
in human pancreatic and prostatic cancer cells [68]. A
recent study suggests that the role of Cx26, unlike Cx43
and Cx32, in suppression of cervical cancer derived
HeLa cell growth likely results from a redistribution of
cAMP throughout the cell population. This function
eliminates the cell cycle oscillations due to higher con-
centration of cAMP required for cell cycle progression
[69]. Tumor cells in G2/M phases of cell cycle are asso-
ciated with low-dose hyper-radiosensitivity (HRS). A re-
cent study reported that Cx43 downregulation, a feature
of the cell at G2M phase, somehow renders tumor cells
hypersensitive to low-dose radiation occurring at G2M
phase is a major cause of HRS in multiple tumor cells in
vitro [70]. The downreguation of cyclin-dependent kin-
ase 6 by miRNA-124-3p transferred between glioblast-
oma cells via gap junctions promotes the anti-
proliferative effect [71]. The different mechanism
involving post-transcriptional regulation of Cx43 is re-
cently reported in H-Ras-transformed cells compared to
non-transformed parental cells; 5′untranslated region
(UTR) is active in Ras-transferred NIH-3 T3 cells while the
3′UTR is active in normal, non-transformed NIH-3 T3 cell
and a regulatory element in the 3′UTR was identified [72].
This study suggests specific regulatory mechanisms in
regulation of connexin expression in cancer cells.
More interestingly, recent studies show that epigenetic
processes play an essential role in regulating connexin gene
expression which includes histone modifications, DNA
methylation and microRNA (see review [73, 74]) A study
shows that downregulation of the microRNA miR218 is
associated with nasopharyngeal carcinoma (NPC), an
Epstein-Barr virus-associated malignancy [75]. Suppression
of miR-218 is related to epigenetic silencing of SLIT2 and
SLIT3, ligands of ROBO receptors involved in tumor
angiogenesis. Moreover, this microRNA directly interacts
with 3′-UTR of Cx43. MicroRNA-206 in mammary cancer
stem-like cells (McCSCs) mediates Zinc-finger transcrip-
tion factor Kruppel-like factor 4 (KLF4) pro-survival signal-
ing through repression of the pro-apoptotic molecules
programmed cell death 4 (PDCD4) and Cx43 [76].
Another study shows miRNA-23a suppresses Cx43 and
impairs osteoblast differentiation of an osteosarcoma cell
line [77]. On the other hand, gap junction communication
can mediate the transfer of some microRNAs between
cells. A recent study reported by Suzhi et al. that gap junc-
tions mediates transport of miRNA-124-3p between cells
and enhances the anti-proliferative effect of this miRNA in
two glioblastoma cells [71]. This is a current active re-
search area and more studies are expected revealing the
mechanistic roles of connexins and gap junctions in facili-
tating the function of miRNAs.
Connexin channels in metastasized cancer cells
and cancer microenvironment
The major questions remain whether connexins are tumor
suppressors or tumor promoters; the situation is much
more complex, and no clear answer can be made thus far.
There are many points to consider. The effect of connex-
ins on tumor progression and behavior depends largely on
endogenous connexin expressed or overexpression of
exogenous connexins on the particular cells and tissue
examined. Furthermore, the inconsistent evidence of con-
nexins’ role in cancer reflects the complexity of develop-
mental stages of cancer progression and metastasis. The
existence of a correlation between connexin expression
and the invasive potential, as opposed to the lack of con-
nexin expression in the earlier proliferation period of can-
cer progression points to a specific function of connexins
during cancer development and metastasis. For example,
Cx43 has a multifaceted function depending upon the
stages of cancers; with low expression in primary tumor
and high expression in metastasized tumor. Cx43 is
involved in neural crest cell migration as a part of normal
development and that impaired gap junction communica-
tion leads to reduced neural crest cell migration [78]. Con-
sistently, in invasive cancers, such as gliomas, increased
Cx43 expression has also been demonstrated to enhance
the cell mobility and invasion [79], which is contrary to
the involvement of Cx43 expression in tumor growth. In
human breast cancer, an earlier study shows that both
Cx26 and Cx43 are upregulated in invasive lesions com-
pared to normal breast cells and cells from non-invasive
lesions, although Cx26 is localized to the cytoplasm,
whereas Cx43 was to intercellular locations [80]. Clinic-
ally, increased expression of Cx26 and Cx43 has been dis-
covered in lymph node metastases of breast cancer, as
opposed to primary breast tumors with decreased ex-
pression of connexins [81]. A narrow range of low doses
of γ-radiation increases Cx43 expression, activation of p38
MAPK/p21 and glioma cell migration, but has no effect
on cell proliferation, and the activation of p38 is inhibited
by Cx43 knockdown, suggesting Cx43 is an important
mediator in MAPK activation and radiation-induced
secondary malignancies and metastasis [82].
In contrast to the inhibitory effect of connexins in pri-
mary tumors, a promoting effect has been found in
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metastatic cancers. Some studies have found that in-
creased gap junction coupling and Cx43 expression con-
tribute to breast cancer adhesion and migration [83].
The establishment of cell-cell communication could be
beneficial in the diapedesis of breast tumor cells during
extravasation through the endothelium. This has been
observed in breast cancer cells, which establish hetero-
typic gap junctions with endothelial cells [84]. Further-
more, overexpression of Cx43 enhances the adhesion of
the cancer cells to the lung endothelial cells [85]. Breast
cancer cells also use Cx43 to initiate brain metastatic le-
sions by forming gap junctions with the endothelial cells
in the vasculature, whereas knocking down connexins by
RNAi or pharmacological methods inhibited brain colo-
nization [86]. Plante et al. showed that in a mouse model
expressing mutant Cx43 (G60S mice), there was a de-
layed onset of palpable mammary gland tumours com-
pared to controls, but an increase in lung metastases,
highlighting the different effects of Cx43 in primary and
secondary tumours [87]. Cx43 levels are well correlated
with Snail-1, a transcription factor which represses
E-cadherin and promotes EMT in prostate cancer cells;
high expression of these two molecules is accompanied
high mobility and elasticity of cancer cells, and the inva-
siveness features of cancer cells [88].
Cancer metastases could also be promoted with the
aid of heterotypic gap junctions formed between the
migrating cancer cells and the target tissue cells. For
example, the formation of heterotypic gap junctions be-
tween a human breast cancer cell line and an osteoblast
cell line has been demonstrated, where the degree of
heterotypic gap junctions relative to homotypic ones
correlated with breast cancer cell metastatic potential
[89]. This data may implicate a mechanism occurring in
breast cancer metastasis to the bone. Heterotypic gap
junction communication between gastric cancer cells
and mesothelial cells appears to play an active role in
peritoneal metastasis. Human gastric cancer cells over-
expressing wild-type and gap junction-impaired Cx43
mutant were co-cultured with human peritoneal meso-
thelial cells, and significant increase in diapedesis and
transmigration of cancer cells through intercellular space
between the mesothelial cells was shown in wild-type
Cx43, not in mutant, expressed cells [90]. The lymphatic
vasculature is a known conduit for metastasis and in-
creased interaction between tumor cells and lymphatic
endothelial cells was thought to play a key role. Adreno-
medullin, a peptide hormone promotes this interaction
and increases gap junction coupling [91]. Blockade of
this heterotypical communication prevents the tumor
cells to migrate through the lymphatic monolayer. A
long-range gap junction signaling model in control of
cancer growth from normal host cells was proposed by
which disruption of gap junction coupling farther away
from oncogene-expressing cells has profound effect in
suppression of tumor incidence [92].
The tumor suppressive effect of connexins has also
been demonstrated in several metastatic cancers. In a
highly metastatic lung cancer cell line, Cx43 expression
was undetected, whereas transfection of Cx43 inhibited
the tumorigenicity of the cells [93]. Similarly, increased
human breast cancer metastatic potential was found to
correlate with decreased Cx43 gene expression and de-
creased gap junction communication [94, 95].
Tumor microenvironment also impacts connexins and
gap junctions in normal cells. It is known that interaction
with mural cells causes endothelial cells of blood vessels
to become quiescent. However, conditioned media col-
lected from breast cancer cells diminishes gap junctional
coupling between mural cells and endothelial cells, and
downregulates Cx43 in mural cells [96]. Additionally,
tumor implantation also significantly increased tumor
vascularization in heterozygous Cx43 knockout mice.
Channel-independent role of connexins in
primary and metastasized cancer
Several published studies suggest that connexin proteins
influence cell cycle and signaling independently of their
roles in forming gap junctions or hemichannels through
its impact on cell cycle and signaling [97]. A recent
study shows that Cx43 expression in four prostate can-
cer cells lines is well correlated with metastatic potential;
however, only knocking down Cx43, not inhibition of
gap junction channels, decreases cell migration and in-
vasion [98]. Connexin proteins are reported to affect the
production and activity of many cell cycle regulators, in-
cluding p27Kip1, cyclin A, cyclin D1, cyclin D2, ERK1/2,
Src, and FGF1 [99–104]. Moreover, the cytoplasmic
C-terminal tail domain of Cx43 alone has been shown
just as effective as the full protein in suppressing neu-
roblastoma progression possibly through its effects on Src
molecule [105]. Another example of the channel-
independent involvement of connexins in tumorigenic cell
signaling and cell cycle was reported by Langlois et al.
[106]. In this study, they examined the effects of Cx43
interaction with the skin tumor suppressor caveolin-1
(Cav-1) in rat epidermal keratinocytes (REK). REK cells
with reduced Cx43 expression exhibited increased
epithelial-mesenchymal transition (EMT) as well as more
invasive features than the control cells. Blocking the gap
junctions with carbenoxolone does not affect the invasive
behavior; thus, connexin channels may not be involved
although carbenoxolone is known to block pannexin
channels as well [107]. This is likely to be caused by the
interaction between the Cx43 C-terminal tail domain and
this interaction is implied to be crucial in suppression of
keratinocyte transformation and invasion. This was also
confirmed in vivo, where the co-localization of Cx43 and
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Cav-1 was reduced in epidermal squamous cell carcinoma
cells. The channel-independent role of connexins has also
been implicated in the regulation of migration and prolif-
eration through its interactions with the actin cytoskel-
eton. The effects of Cx43 in mediating the regulation of
the actin cytoskeleton was studied in human glioma cells
[108]. Two truncated constructs of Cx43: one lacking the
C-terminal tail domain and one lacking the entire trans-
membrane domain are used, and there is a similar reduc-
tion in the proliferation of glioma cells regardless of
whether the truncated or full length versions of Cx43 are
used. Truncated Cx43 does not alter gap junction coup-
ling and furthermore, Cx43 C-terminal tail domain is
sufficient to promote migration of glioma cells. The
C-terminal tail domain is associated with a lamellipodia-
type migration, which implies the involvement of Cx43 in
the regulation of the actin cytoskeleton. Additionally, cell
mobility of glioma cells is not affected by gap junction in-
hibitors, whereas only cells overexpressing full-length
Cx43, not truncated Cx43 without the C-terminal tail do-
main increases mobility [79]. A recent study showed that
Cx43 increased sensitivity to sunitinib-induced cytotox-
icity in malignant mesothelioma cells, and this effect is in-
dependent of gap junctions and is likely exerted through
its direct interaction with apoptotic factor Bax [109]. Cx37
suppresses cancer cell growth and six extracellular cyst-
eine residues involved in gap junctional docking were in-
dividually mutated. Of six mutants, three traffic to the
plasma membrane as wild-type Cx37, but none form func-
tional gap junctions and two form hemichannels. How-
ever, none of these mutants affect insulinoma (Rin) cell
proliferation [110]. Moreover, by using domain swapping
chimeric mutants, C-terminus and pore-forming domains
are found to be essential to the role of Cx37 in growth
suppression of Rin cells [111].
The effect of Cx43 expression on the regulation of cell
cycle was investigated in HeLa cells transfected with
Cx43 and primary human foreskin fibroblasts (HFF) pre-
dominantly expressing Cx43 [112]. 18-α-glycyrrhetinic
acid (GA) was used to reduce gap junctional coupling
but not affect Cx43 expression, and sodium butyrate
(NaBu) or anti-arrhythmic peptide (AAP10) were used
to enhance Cx43 expression in the cells. Using time-
lapse microscopy, it was discovered that the increase in
Cx43 expression levels delayed mitotic durations, which
corresponded with an accumulation of cells in the G1
phase, leading to a reduction in cell proliferation. This
was linked to the increased expression of p21waf1/cip1,
which is a cell cycle inhibitor. These effects were unre-
lated to Cx43 channel function. Overall, it is suggested
that the upregulation of Cx43 expression delays the rate
of cell cycle through the delay of G1, thereby increasing
time between mitotic cycles; however, the underlying
mechanism remains largely elusive.
Connexin channels in clinical studies and
potential cancer therapeutics
There are several plausible strategies in the development
of potential therapeutics. The initial attempts to reverse
the lack of gap junctional communication known in
tumorigenic cells were accomplished through chemical
treatments, including retinoids, vitamin D, carotenoids,
and cAMP [113]. By taking an advantage of inclusive
gap junction communication only between tumor cells,
not with surrounding cells, tumor cells were loaded with
Lucifer yellow (LY) and implanted into tumor in situ. By
irradiation with blue light, only tumor cells containing
Lucifer yellow died, not surrounding cells without LY
[114]. Furthermore, these experiments of forced re-
induction of gap junction communication between a
tumor cell and a non-tumorigenic cell were able to pre-
vent the growth of transformed cells [115]. Cx43 gap
junctions are reduced in breast cancer and effects have
been made to restore gap junction activity in these cells.
A therapeutic peptide ACT1 enhances Cx43 gap junc-
tion function and impairs proliferation or survival of
breast cancer cells [116]. Additionally, combination of
ACT1 with tamoxifen or lapatinib augments the effects
of these drugs on ER+ or Her2+ breast cancer cells,
respectively. However, it is important to note that the
recovery of gap junction coupling does not always auto-
matically entail normalization of the tumor cells. Carbon
monoxide is emerging as a promising molecule to treat
several diseases including cancer. It can directly or indir-
ectly inhibit the function of connexin hemichannels
[117, 118] although the role of hemichannels in cancer
cells is yet to be uncovered. Ganoderma lucidum, an
herbal mushroom increases Cx43 expression and in-
hibits growth of human ovarian cancer cells, and this
growth inhibition was abrogated by knocking down
Cx43 gene [119]. The bioactive substance sulforaphane
inhibits cancer stem cells in pancreatic ductal adeno-
carcinoma through the increased Cx43 and E-cadherin
expression, altered activation of several kinases and en-
hanced gap junction channels [120]. Several lipophilic
statins are suggested as antineoplastic agents. A recent
paper shows that the effect of simvastatin is mediated by
Cx43 gap junctions via inhibition of phosphorylation of
Cx43 by PKC [121]. All these studies implicate Cx43 as
a potential therapeutic target. Indeed, Cx43 antibody
against extracellular loop domain was tested in Wistar
rats with induced C6 glioma [122]. Treatment with this
antibody increased median survival to 39.5 days com-
pared to 28 days without treatment, and combined treat-
ment with radiotherapy increased survival to 60 days.
Antibody against Cx43 E2 domain blocks Cx43 hemichan-
nels [123]; thus Cx43 hemichannels is likely involved in
the growth of glioma cells. In addition to Cx43, small
interfering RNA (siRNA) was used to knockdown Cx37
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expression in subcutaneous gastric tumors in mice [124].
Their results show that the level of Cx37 siRNA is
negatively correlated with gastric cancer development and
reduction of Cx37 expression promotes tumor cell
apoptosis.
Expression of connexin subtypes are differentially
regulated not only during metastasis but also during
self-renewal of cancer cells. Among 131 cases of human
astrocytic tumors, Cx43 was observed in 76.9 % of dif-
fuse astrocytoma and in all cases of anaplastic astrocy-
toma and glioblastomas [125]. Cx46 was also detected in
glioblastoma cancer stem cells, while Cx43 is predomin-
antly expressed in non-stem cells [126]. Interestingly,
during differentiation, Cx46 is reduced and Cx43 is
increased, and targeting Cx46 reduces stem cell main-
tenance. Furthermore, by analyzing connexin subtype
expression data of 1809 and 1899 breast cancer from
Affymetrix and illumine arrays, respectively as well as
127 patients with all tumor grades, a correlation was
established; elevated Cx43 protein levels were linked
with improved breast cancer outcome while elevated
Cx30 levels were associated with a reduced disease
outcome [127]. Thus, Cx43 and Cx30 were suggested as
potential independent prognostic markers for breast
cancer. Cx30 gene was deleted in 25.8 % of 751 and mu-
tated in 15 % of 158 gliomas and protein was absent in
28.9 % of 145 tumors [128]. However, consistent with
Cx30 in breast cancer, Cx43 level is inversely correlated
to survival in 2 cohorts of glioblastoma patients. Cx43
was also found to protect glioblastoma cells against
radiation-induced DNA damage. The correlation of ex-
pression of adhesion molecules and connexin subtypes is
also investigated in human colorectal cancer; a positive
correlation between Cx26 and Cx32, but not Cx43 and
adhesive proteins in patients without lymph node
metastases while a positive association between Cx43
and E-cadherin with lymph node metastases [129]. Cx43
expression is correlated with oral squamous cell carcin-
oma and the overall survival time, and is proposed as an
independent prognostic biomarker [130]. In another
study, connexin expression was evaluated in 96 breast
cancer patients before and after neoadjuvant chemo-
therapy [131]. Cx32 is positively correlated with HER2
expression pre-chemotherapy and with Ki67, a cell pro-
liferation marker, post-chemotherapy, while Cx46 is
negatively correlated with Ki67 and positively with better
survival in both pre- and post-chemotherapy groups,
suggesting that Cx26 and Cx46 could be utilized to as-
sess prognosis and therapeutic outcomes. Reduction of
Cx43 level is also suggested as a reliable marker for the
prediction of cisplatin-based chemotherapy outcome and
prognosis for patients with advanced non-small cell lung
cancer [132]. Cx43 expression is also reported to correl-
ate with early tumor recurrence, disease-free survival
and overall survival in hepatitis B virus (HBV)-related
hepatocellular carcinoma (HCC), implying Cx43 may
delay early HCC recurrence, metastasis and poor prog-
nosis after radical hepatectomy [133]. Therefore, under-
standing the specific expression pattern of connexins in
various tumors could help establish new prognostic
biomarkers and offer targeted, specific options for can-
cer treatment.
Drug resistance is a major challenge for cancer treat-
ment. Cisplatin is a commonly used chemotherapeutic
agents for advanced non-small cell lung cancer, but pro-
longed treatment acquires resistant due to development
of EMT [134]. Overexpression of Cx43 reverses EMT
and cisplatin resistance whereas Cx43 deletion initiates
EMT and drug resistance. Patients with glioblastoma
multiforme (GBM), an aggressive adult primary brain
tumor with poor prognosis, develop resistance to the
frontline chemotherapy, temozolomide (TMZ) a chemo-
therapeutic agent. In contrast to the situation in lung
cancer, Cx43 was increased with the formation of cell-
cell communication in the resistant tumor cells and this
increase was induced by epidermal growth factor recep-
tor (EGFR) activated JNK-ERK1/2-AP-1 signaling [135].
Another related study showed that Cx43 expression in
human glioma cells enhances resistance to TMZ via a
mitochondrial apoptosis pathway by the reduction in
Bax/Bcl-2 ratio and the release of cytochrome C [136].
These studies suggest that reduction of Cx43 could help
sensitize resistant cells to the chemotherapy.
Recently, a new paradigm was proposed by Colin
Green’s laboratory based on the data obtained in chronic
inflammatory disorders and trauma in the eye that pro-
tecting, maintaining or restoring cancer vasculature
leads to reduced tumor hypoxia and promotes the sur-
vival of normal cells [137]. Given that Cx43 hemichan-
nels are involved in vascular leakage and endothelial cell
death [138], modulation of these channels may provide
an alternative for cancer treatment. Together, with ad-
vanced understanding of the mechanism of connexin
and connexin channels in various types and stages of can-
cer development and metastasis, drugs targeting connex-
ins in cancer cells or/and host normal cells in next phase
of cancer therapy are getting closer to become reality.
Pannexin channels in cancer
There are several examples of human diseases that are
either directly or indirectly linked to pannexins, in par-
ticular, Panx1. This is not that surprising given that pan-
nexins are involved in taste sensation, airway defense,
viral infection (HIV), the immune response, ischemic
cell death, seizures, apoptosis and the differentiation of
keratinocytes, chondrocytes, and neurons [139, 140]. Pan-
nexins are also present and play an important role in the
development of several tissues and cell types [139–142]
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and have been implicated in cell proliferation [11, 23, 143],
differentiation [144], and inflammation [32]. Collectively,
trends in pannexin links to disease support the notion that
reduced levels of pannexin channels can be protective
against disease onset and progression. For instance, in
adult mice Panx1 expression has been shown to have a
deleterious effect in neurodegeneration [145], ischemia
[146–148], epileptic seizures [149, 150], and Crohn’s
disease [151]. It is therefore possible that Panx1 expres-
sion may be needed at early stages of development, but
needs to be down-regulated in the adult to avoid the
negative effects of its expression in pathological states
including cancer.
Pannexin 1 upregulation or gain-of-function in
cancer
Our current knowledge of Panx1 function in cancer is
limited (see Table 2). However, the majority of published
reports, with three notable exceptions [3, 152, 153]
indicate that amplification or upregulation of Panx1 is
prevalent in cancer cell lines and tumors compared to
normal tissues. In some cases, the knockdown of Panx1
can revert the cancer cells to a more normal phenotype,
as we reported for B16-BL6 mouse melanoma cells,
described in detail below [154]. Other examples include
the human glioma cell line U87-MG that had a sig-
nificant reduction in proliferation upon Panx1 siRNA
treatment [155]. Similarly, higher expression of Panx1 is
present in human leukemic lymphocytes than in normal T
cells [156]. At the transcript level, Panx1 over-expression
was linked to higher metastatic spread in syngeneic
hepatocarcinoma cell lines of different metastatic abilities
based on microarray analysis [157]. Similarly, ampli-
fication and over-expression of Panx1 was reported in
aggressive multiple myeloma cell lines [158]. In tissues,
upregulation or amplification of PANX1 was reported in
human biopsies from most cancer types according to the
analysis of cross-cancer alterations in the 89 cancer stud-
ies included on the cBioPortal.org for Cancer Genomics
[159, 160]. However, the Cancer Genome Atlas also
reports some examples of PANX1 deletions present in
human biopsies, indicating that Panx1 expression could
be regulated differently in specific cancer types. At the
protein level, Panx1 expression is listed in 17 out of 20
tumour types (high in colorectal, lung, urothelial and
stomach cancers), and up to 70 % of human melanoma
tumours show high levels of Panx1 protein (Human
Protein Atlas [161]).
The most recent report of the role of Panx1 in cancer
was published by Furlow et al. in the journal of Nature
Cell Biology [162]. In this study, Panx1 was found to be
expressed in many breast cancer cell lines, and a trun-
cated mutant form of Panx1 was particularly enriched in
highly metastatic breast cancer lines like CN-LM1A and
MDA-LM2. The mutation was not found in the less ag-
gressive parental cell lines CN34 and MDA-MB-231.
This mutation (C268T) results in a truncated protein
Panx11–89that only contains the N-terminus, first trans-
membrane domain and part of the first extracellular loop
of Panx1. This mutant form is not functional on its own
but when co-expressed with full-length Panx1 has a gain-
of function effect on channel activity [162]. Interestingly,
Table 2 Summary of the current literature on the role of pannexin channels in different cancer types
Pannexin Cancer type Description Reference
Panx1 Breast Gain of function mutation in PANX1 increases metastasis [162]
Panx1 Melanoma Upregulated expression. Knockdown induces re-differentiation [33, 154]
Panx1 Glioma Tumour suppressor when overexpressed in Panx1-deficient rat C6
glioma cells, but endogenously expressed in human glioma cell lines.
Accelerates glioma tumor aggregate formation
[153, 181]
Panx1 Glioma Panx1 siRNA reduces proliferation of U87-MG human glioma cells [155]
Panx1 Hepatocellular carcinoma Upregulation linked to cancer spread in aggressive Hca-F cell lines [157]
Panx1 Multiple myeloma Gene amplification and upregulation in myeloma cell lines [158]
Panx1 Colon Interaction with Liver X receptor β for pyroptotic cell death [178]
Panx1 Leukemia
Osteosarcoma
Upregulated in leukemic cells compare to T-cells.
Activated by chemotherapy drugs and immunogenic therapy to release ATP
[156, 186]
Panx1 Prostate Bystander cell killing effect of TMPK/AZT [185]
Panx1 Gall bladder adenocarcinoma Downregulated expression in tumours [3]
Panx2 Glioma Tumour suppressor overexpressed in C6 glioma cells. Downregulated
in human tumours and positive correlation with patient survival
[179, 183]
Panx2 Hepatocellular carcinoma Potential tumour suppressor. Methylated in cancer samples [184]
Panx2 Neuroblastoma Knockdown in Neuro2a cells increases differentiation [21]
Panx1, Panx3 Basal and squamous skin cell carcinoma Downregulated in BCC and SCC tumours compared to normal skin [152]
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this same mutation had been previously reported in the
Cancer Genome Atlas (TCGA) as K91del in patient biop-
sies from invasive breast carcinoma [159, 160]. Furlow et
al. elegantly showed that breast cancer cells expressing the
mutant Panx1, increase ATP release in vitro and in vivo
under conditions of membrane stretch where the
mechano-sensitive Panx1 channel is activated. They
propose that this type of activation may occur due to
mechanical deformation of the cells in the microvascula-
ture of secondary organs during metastasis. Cells that
express the mutant Panx1 have a survival advantage in
metastatic progression since the ATP released acts on pur-
inergic receptors (P2Y) to suppress apoptosis and reduce
cell death in those tight spots of the microvasculature.
This study not only described a clear role for Panx1 in
cancer metastasis, but also highlighted the possibility of
using pharmacological inhibition of the Panx1 channel in
mouse models with known channel blockers such as
Carbenoxolone as a new therapeutic option to reduce
breast cancer metastasis [162].
Panx1 in melanoma and links to inflammation
Melanomas account for 80 % of all skin cancer-related
deaths [163], and in spite of recent progress with tar-
geted and immuno-therapies [164] such as BRAF/MEK/
ERK/c-KIT inhibitors, with limited success in long term
disease control [165], there is still a desperate need for
effective treatment options for this highly metastatic
disease [166]. We have previously shown that mouse
melanocytes have low Panx1 expression while the
aggressiveness of isogenic melanoma cell lines [167]
(B16-FO, F10 and BL6) is directly correlated to their
Panx1 levels, with no detectable Panx2 or Panx3 ex-
pression [154]. Knocking down Panx1 with shRNA in
aggressive BL6 cells, changed cell morphology into a
normal melanocytic phenotype, increased differentiation
and melanin production, reduced migration and prolifer-
ation and affected the expression of malignant markers
such as vimentin [154, 168]. In a chick-chorioallantoic
membrane assay [169–172] (chick-CAM), the mouse mel-
anoma tumors with Panx1 shRNA were significantly
smaller and had less instances of metastasis to the liver
than the aggressive wild-type cells with high Panx1 [154].
We proposed Panx1 as an interesting new target for thera-
peutic intervention in the fight against melanoma.
Recently, two articles have highlighted the link
between inflammation and melanoma, proposing the
involvement of the Panx1/P2X7 complex as a key regu-
lator [33, 173]. The Panx1/P2X7 complex has been
shown to activate the NLRP3 inflammasome and partici-
pate in the release of IL-1β in vitro [34, 174, 175]. It is
known that the NLRP3 inflammasome is constitutively
activated in melanoma cells, and late-stage melanoma
cells can autonomously secrete IL-1β [176]. IL-1β is a
pro-inflammatory cytokine involved in many processes
including cell proliferation, tissue regeneration and im-
mune regulation. It is also a tumor promoting factor im-
plicated in cancer progression, increasing angiogenesis,
invasion and metastasis (as reviewed by [177]). Addition-
ally, IL-1β may also drive expression of cyclooxygenase-
2 (COX2) which leads to high levels of prostaglandin E2
[33]. In the proposed model, ATP activates the Panx1/
P2X7 complex to open (in a mutated melanocytic cell)
and allows the cation flow that activates the NLRP3
inflammasome composed of NLR (nucleotide oligome-
rization domain-like, leucine-rich repeat containing
receptor), ASC (apoptosis associated speck-like protein
containing a caspase recruitment domain (CARD)), and
caspase-1. Activated caspase-1 cleaves and activates the
cytokines (IL-18 and IL-1β). IL-1 can then increase ex-
pression of COX-2 and PGE2. Both IL-1β and PGE2 can
be released from the cell to act on the microenviron-
ment. The effects would include increased cell prolifera-
tion, angiogenesis, tumor invasiveness and growth, and
recruitment of pro-inflammatory cells. Other mutations
in the melanoma cell alter normal growth cycle feed-
back, and with this inflammasome activation, may con-
tinue to proliferate without control [33]. A caveat to this
model is the possibility that high levels of ATP may do
the opposite and reduce growth and tumorigenicity in
cancer cells as pointed out by Mantel and Harvey [173].
Additionally, this same pathway involving the NLRP3
inflammasome, can result in the activation of cell death
and pyroptosis, which would have the opposite effect.
This alternative route of the NLRP3 signalling model
was shown recently to also involve Panx1 [178]. In colon
cancer cells that express liver X receptors (LXRs), P2X7
receptors and Panx1, it was proposed that the LXR
ligand would bind its receptor and facilitate LXR’s
association with Panx1. This new complex allows the
opening of Panx1 channels to release ATP for autocrine
activation of P2X7 receptors. The P2X7 activation then
leads to NLRP3 inflammasome assembly, and activated
caspase-1 that induces colon cancer cell pyroptosis and
death [178]. In conclusion, Panx1/P2X7 is upstream of
the NLRP3 inflammasome, but two different arms of its
downstream signalling pathway could be either implicated
in tumorigenesis in the case of melanomas, or cell death
in the case of colon cancer cells that express LXRs.
Downregulation of Pannexin expression in cancer
As was mentioned before, even though the majority of
reports in the literature to date point towards an over-
expression or amplification of Panx1 in cancer cells and
tumours, there are also important exceptions to this
trend. In fact, one of the first papers involving Panx1
and cancer reported that while Panx1 mRNA was
expressed in primary astrocytes, it was not expressed in
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the C6 rat glioma cell line. Paradoxically, the authors re-
ported four human glioma cell lines (U87, U251, SF188
and SF539) that were all positive for Panx1 at the tran-
script level, indicating that there might be some differ-
ences among species in terms of Panx1 expression in
gliomas. Additionally, when Panx1-GFP was overex-
pressed in C6 glioma cells [153, 179], it appeared to have
a tumour suppressive effect. These latter findings are
complicated to interpret as we now know that the GFP
tag has a negative effect on the Panx1 channel function
and trafficking [180]. However, it is possible that pan-
nexins may have different roles in different cancer sub-
types, as pointed out in the previous section where the
co-expression of additional receptors (such as LXR) may
affect the downstream signaling consequences and result
in different cellular outcomes. Interestingly, these C6 gli-
oma cells stably expressing Panx1-GFP were also used to
demonstrate in a later report, that Panx1 expression can
accelerate the assembly of multicellular tumor aggre-
gates through an interaction with F-actin microfila-
ments. The formation of these large cellular aggregates
is a key step in glioma progression [181].
A second case of downregulation of Panx1 in cancer
tissues was reported in a review paper by Schalper et al.
[3] where immunohistochemistry of normal human
gallbladder and gallbladder adenocarcinoma with anti-
Panx1 antibodies indicated a lower expression of Panx1
in tumour cells. Additionally, using Ki67 labeling along
with Panx1 immunostaining, the authors concluded that
Panx1 expression was negatively correlated with prolifer-
ation in gallbladder carcinomas [3].
The third example of downregulation of pannexins in
tumours was reported in non-melanoma skin cancer
samples from human biopsies by our collaborators [152].
While Panx1 and Panx3 are expressed in normal adult
human facial skin, their expression is not detectable in
either basal or squamous cell carcinomas immuno-
stained with anti-pannexin antibodies. This apparent
downregulation of Panx1 and 3 in keratinocytic tumours
may indicate a protective role of these pannexins against
keratinocyte transformation [152]. However, it is also
possible that cells that originally express pannexins in
these type of tumours, may go through the keratinocyte
life cycle at a higher rate to proliferate, differentiate and
undergo programmed cell death, and are therefore not
detectable in advanced skin cancer biopsies.
Pannexin 2 as a tumour suppressor
In the pannexin family, Panx2 and Panx3 are not as well
characterized as their more popular and ubiquitously
expressed sibling. Therefore, our understanding of the
role of these two isoforms in cancer is limited. Panx3
plays a role in proliferation and differentiation of cells in
skin, cartilage and bone [182], so we predict that we will
soon learn more about a potential role for Panx3 in skin
cancer and osteosarcomas. Panx2 has been proposed to
play an important role as a tumour suppressor in brain
tumours and hepatocellular carcinomas (Table 2).
Litvin et al. was the first to publish the initial evidence
of a down-regulation of human Panx2 transcripts in
Affymetrix chip analysis, particularly in astrocytomas,
glioblastoma multiforme (GBM), and oligodendro-gliomas
[183]. Additionally, in Kaplan-Meier survival plots of dif-
ferential expression of Panx2 in human tumour samples,
there was a positive correlation between Panx2 expression
and patient survival [183].
Lai et al. [179] described the downregulation of Panx2
mRNA in C6 glioma cells, which was consistent with a
reduction or absence of expression in human glioblast-
oma, glioma and GBM cell lines at the transcript level
compared to normal astrocytes and human brain.
Importantly, the over-expression of Panx2-GFP or
Panx2-HA in C6 cells changed cell morphology, reduced
cell growth and anchorage-independent growth. Over-
expressed Panx2-HA or -GFP tagged proteins had a
significant reduction in in vivo tumour growth in nude
mice when compared to controls [179].
Consistent with a potential role as tumour suppressor,
a recent publication listed PANX2 as one of the methyl-
ated genes identified by expression profiling and DNA
methylation arrays in hepatocellular carcinomas (HCC)
[184]. In HCC, the hepatocyte growth factor (HGF) up-
regulates the expression of DNA methyltransferase 1
that results in the hypermethylation and epigenetic re-
pression of potential tumour suppressor genes, including
PANX2. Recently, Le Vasseur et al. demonstrated that
Panx2 expression is not limited to the central nervous
system as was originally proposed, and it was shown to
be expressed in liver among many other organs and tis-
sues [20]. Therefore, it is possible that Panx2 expression
is silenced upon transformation in many tissues.
Chemotherapeutic agents and Panx1 channels
As we discussed earlier, Panx1 is commonly expressed
and even upregulated in many cancer cells. An unex-
pected side effect of this Panx1 expression, other than
its potential role in cancer progression, is the possibility
that Panx1 channels in the presence of different chemo-
therapeutic drugs, can actually be exploited to enhance
cancer cell death. One example of this was seen in pros-
tate cancer PC-3 cells engineered by gene therapy to
produce a variant of human thymidylate kinase (TMPK)
that can potentiate the drug azido thymidine (AZT).
Panx1 is necessary for this effective bystander cell killing
of neighbouring cells after suicide gene therapy delivered
by lentivirus [185]. However, the authors propose that
this effect is the result of Panx1 gap junctions between
cells, and the effect is abolished by treatment with
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carbenoxolone. In this case, since the cells express high
levels of Cx43, the observed effect may be due to real
connexin gap junctions, even if not detected as plaques
at the cell surface as was expected by the authors [185].
Some more clear examples of the role of Panx1 chan-
nels in the presence of chemotherapeutic drugs were re-
ported by Boyd-Tressler et al. [156] and Martins et al.
[186]. The first group showed upregulation of Panx1 in
leukemic cells compared to normal T-cells. In Jurkat
cells they observed that in the presence of different
chemotherapy drugs that induce apoptosis, Panx1 chan-
nels were cleaved by caspase-3 to remove the C-tail
inhibitory fragment and were activated to open and re-
lease ATP, ADP and AMP. These nucleotides can also
be released by other Panx1-independent mechanisms,
and are very important as paracrine signals to effector
leukocytes that mediate the immune response against
the dying tumor cells [156]. A similar effect was ob-
served in Panx1-expressing human osteosarcoma cells
(U2OS) and fibrosarcomas (MCA205) that were chal-
lenged with immunogenic cell death- inducing antineo-
plastic agents (oxaliplatin, anthracyclines) [186]. During
cell death, the release of ATP happens in this case,
through a different mechanism that involves lysosomal
exocytosis. The effect of caspases and the opening of
Panx1 channels is required for the translocation of
LAMP1 to the cell surface for ATP release [186].
It is encouraging to think that Panx1 could be used as
a biomarker in different cancers, but also as a conduit of
ATP that assists the process of cancer cell death by
existing chemotherapies, and facilitates immune recogni-
tion of the targeted tumour.
Panx1 channel blockers and their potential
therapeutic use in cancer
There are now several compounds that have been reported
in the literature to efficiently block Panx1 channels that
could be used as new therapeutic alternatives. Namely, pro-
benecid (PBN) [180, 187, 188], carbenoxolone [189, 190],
trovafloxaxin (Trova) [191], and mefloquine (MFQ) [192]
have been successfully used in vitro and/or in vivo to close
Panx1 channels with no reported significant side effects.
However, as with any chemical blocker, there are also many
unspecific effects reported that should be taken into ac-
count. At present PBN (used in the past for long-term
treatment of gout as it interferes with the organic anion
transporter) is frequently used as Panx1 channel inhibitor
[180, 187]. In fact, PBN has been recently used as an effect-
ive adjuvant therapy to sensitize breast cancer cells and en-
hance bisphosphonate chemotherapy anti-tumor effects
[193]. CBX has also been shown to be specific to Panx1 in
lower doses, because at higher doses (>100 μM) it may also
block connexin hemichannels [180, 187]. MFQ (a malaria
drug), has been used successfully in mice to block Panx1
[192, 194–196]. Trova is an antibiotic (toxic in high doses)
that has been recently reported to specifically block Panx1
as well [191]. In addition to these compounds, there are
other small molecule inhibitors such as the 10Panx1 peptide
[147, 197] and specific anti-Panx1 antibodies [148] that
have also been widely tested for their inhibitory effects on
Panx1 channel function. These are tools that could be
exploited as different ways of inhibiting the Panx1 channel
that may prove useful as novel treatments in the fight
against different cancers.
Conclusions
Cancer is not a single disease but a term that includes many
different and complex diseases. The role of cellular commu-
nication in cancer, facilitated by the connexin and pannexin
families of channel-forming proteins is also of a complex
nature. There are 21 connexins and 3 pannexins in the hu-
man genome, making it challenging to generalize about
their overall function in cancer. In very general terms, the
current literature would support a tumour suppressor role
for connexins in early stages of cancer progression, with an
opposing role in late-stage (or advanced) cancer and metas-
tasis. On the pannexin side, the majority of reports point to-
wards a tumour promoting effect of Panx1 expression.
However, this effect may be different for the other pannexin
members, and may also be tissue- and cancer- specific. Our
developing knowledge of the mechanisms that regulate gap
junctions, connexin hemichannels, and pannexin channels
in the different cancer types will allow us to better target
connexins and pannexins as new candidates for therapeutic
intervention.
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